Matches in Nanopublications for { ?s ?p "[A point mutation (V600E) in the BRAF oncogene is a prognostic biomarker and may predict for nonresponse to anti-EGFR antibody therapy in patients with colorectal carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- assertion description "[A point mutation (V600E) in the BRAF oncogene is a prognostic biomarker and may predict for nonresponse to anti-EGFR antibody therapy in patients with colorectal carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[A point mutation (V600E) in the BRAF oncogene is a prognostic biomarker and may predict for nonresponse to anti-EGFR antibody therapy in patients with colorectal carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1076186.RAiaOCQN-W-g62lvik9YfAmVAoY_8YqM5s1IUaxfFsMoE130_assertion description "[A point mutation (V600E) in the BRAF oncogene is a prognostic biomarker and may predict for nonresponse to anti-EGFR antibody therapy in patients with colorectal carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1076186.RAiaOCQN-W-g62lvik9YfAmVAoY_8YqM5s1IUaxfFsMoE130_provenance.
- NP1076187.RAObxmg_n8AO39HDliJu1G8qBFtwIGLE78rhTgfslFSJU130_assertion description "[A point mutation (V600E) in the BRAF oncogene is a prognostic biomarker and may predict for nonresponse to anti-EGFR antibody therapy in patients with colorectal carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1076187.RAObxmg_n8AO39HDliJu1G8qBFtwIGLE78rhTgfslFSJU130_provenance.